METHODS	The stage IIB-IIIB cervical cancer patients were randomized to have Tegafur-Uracil 225 mg/m ( 2 ) / day orally , 5 days a week and carboplatin 100 mg/m ( 2 ) IV over 30-60 min , weekly on day 1 concurrent with standard radiotherapy ( Group A ) or carboplatin alone concurrent with standard radiotherapy ( Group B ) .\